Pasar al contenido principal

INTERES PRONOSTICO Y TERAPEUTICO DE LAS PROTEINAS SLC Y ABC EN ADENOCARCINOMAS HEPATICOS Y GASTROINTESTINALES

PI19/00819

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Centro realización INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia

  • Alonso-Peña, Marta|||0000-0003-0934-2202
  • Espinosa-Escudero, Ricardo
  • Herraez, Elisa
  • Briz, Oscar
  • Cagigal, Maria Luisa
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Fernandez-Rodriguez, Conrado
  • Bujanda, Luis|||0000-0002-4353-9968
  • Calvo Sanchez, Marta
  • D'Avola, Delia
  • Londoño, Maria Carlota|||0000-0002-6533-1586
  • Diago, Moises|||0000-0002-8583-2433
  • Fernandez-Checa, Jose C.
  • Garcia-Ruiz, Carmen
  • Andrade, Raúl J.
  • Lammert, Frank
  • Prieto, Jesus
  • Crespo García, Javier|||0000-0001-8248-0172
  • Juamperez, Javier|||0000-0002-8556-6374
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Monte, Maria J.|||0000-0003-1844-7428
  • Marin, Jose J. G.|||0000-0003-1186-6849
A variant (p.Arg225Trp) of peroxisomal acyl-CoA oxidase 2 (ACOX2), involved in bile acid (BA) side-chain shortening, has been associated with unexplained persistent hypertransaminasemia and accumulation of C27-BAs, mainly 3α,7α,12α-trihydroxy-5β-cholestanoic acid (THCA). We aimed to investigate the prevalence of ACOX2 deficiency-associated hypertransaminasemia (ADAH), its response to ursodeoxycholic acid (UDCA), elucidate its pathophysiological mechanism and identify other inborn errors that could cause this alteration. Among 33 patients with unexplained hypertransaminasemia from 11 hospitals and 13 of their relatives, seven individuals with abnormally high C27-BA levels (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outcome of liver cancer patients with SARS-CoV-2 infection, An International, Multicentre, Cohort Study

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Ríos, José|||0000-0002-0716-8784
  • Bouattour, Mohamed|||0000-0002-3919-4135
  • El-Kassas, Mohamed|||0000-0002-3396-6894
  • Leal, Cassia R. G.
  • Mocan, Tudor|||0000-0001-7785-6403
  • Nault, Jean-Charles|||0000-0002-4875-9353
  • Alves, Rogerio C. P.
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • García-Juárez, Ignacio|||0000-0003-2400-1887
  • Pinato, David James|||0000-0002-3529-0103
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Alvares-da-Silva, Mario R.|||0000-0002-5001-246X
  • Bandi, Juan C.|||0000-0001-9733-1938
  • Rimassa, Lorenza|||0000-0001-9957-3615
  • Lozano, Mar|||0000-0001-7099-0810
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Tacke, Frank|||0000-0001-6206-0226
  • Sala, Margarita
  • Anders, María|||0000-0002-2238-5322
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Piñero, Federico
  • França, Alex
  • Guarino, Maria|||0000-0002-0460-4122
  • Elvevi, Alessandra
  • Cabibbo, Giuseppe|||0000-0002-0946-3859
  • Peck-Radosavljevic, Markus|||0000-0002-0597-2728
  • Rojas, Ángela|||0000-0003-0853-4800
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Braconi, Chiara|||0000-0003-4835-1259
  • Pascual, Sonia|||0000-0002-4265-5019
  • Perelló, Christie|||0000-0003-0234-2330
  • Mello, Vivianne
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Acevedo, Juan|||0000-0003-4507-2422
  • Villani, Rosanna|||0000-0001-9875-019X
  • Hollande, Clemence|||0000-0002-2287-0635
  • Vilgrain, Valérie
  • Tawheed, Ahmed|||0000-0002-9382-8733
  • Ferguson Theodoro, Carmem|||0000-0001-6605-1060
  • Sparchez, Zeno
  • Blaise, Lorraine
  • Viera-Alves, Daniele E.
  • Watson, Robyn
  • Carrilho, Flair J.
  • Moctezuma-Velázquez, Carlos|||0000-0003-2367-2742
  • D'Alessio, Antonio
  • Iavarone, Massimo|||0000-0003-3493-6504
  • Reig, María|||0000-0002-5711-9534
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p =.0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p =.5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p =.0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.